Alfacalcidol | List of Frontiers open access articles

Original Research

Published on 01 Feb 2024

Effects of active vitamin D analogues on muscle strength and falls in elderly people: an updated meta-analysis

in Endocrinology of Aging

An Xiong
Haibo Li
Miaoying Lin
Feng Xu
Xuedi Xia
Dexing Dai
Ruoman Sun
Yali Ling
Lei Qiu
Rui Wang

Frontiers in Endocrinology

doi 10.3389/fendo.2024.1327623

8,170 views
15 citations

Original Research

Published on 21 Jan 2022

Cholecalciferol vs. Small Doses of Alfacalcidol vs. Placebo in Chronic Kidney Disease Patients on Hemodialysis: A Randomized Parallel Group Study

in Nephrology

Joanna Matuszkiewicz-Rowińska
Paweł Kulicki
Paweł Zebrowski
Wiesław Klatko
Antoni Sokalski
Stanisław Niemczyk
Magdalena Wypych-Birecka
Jolanta Małyszko

Frontiers in Medicine

doi 10.3389/fmed.2021.781191

16,032 views
9 citations

Original Research

Published on 12 Aug 2021

Association Between Secondary Hyperparathyroidism and Body Composition in Pediatric Patients With Moderate and Advanced Chronic Kidney Disease

in Pediatric Nephrology

Vasiliki Karava
Antonia Kondou
John Dotis
Athanasios Christoforidis
Anna Taparkou
Konstantina Tsioni
Evangelia Farmaki
Konstantinos Kollios
Ekaterini Siomou
Vassilios Liakopoulos

Frontiers in Pediatrics

doi 10.3389/fped.2021.702778

4,292 views
4 citations

Original Research

Published on 27 Nov 2025

Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis

in Pharmacogenetics and Pharmacogenomics

Zhi-Hu Zhao
Tao Ling
Songqing Ye
Wei Luo
Jian-Xiong Ma
Xinlong Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1566890

2,010 views
2 citations

Systematic Review

Published on 19 Apr 2022

Efficacy and Safety of Eldecalcitol for Osteoporosis: A Meta-Analysis of Randomized Controlled Trials

in Bone Research

Hongyan Liu
Guoqi Wang
Ting Wu
Yiming Mu
Weijun Gu

Frontiers in Endocrinology

doi 10.3389/fendo.2022.854439

8,766 views
12 citations

Case Report

Published on 30 Jun 2022

Case Report: Inactivating PTH/PTHrP Signaling Disorder Type 1 Presenting With PTH Resistance

in Pediatric Endocrinology

Tanguy Demaret
René Wintjens
Gwenaelle Sana
Joachim Docquir
Frederic Bertin
Christophe Ide
Olivier Monestier
Deniz Karadurmus
Valerie Benoit
Isabelle Maystadt

Frontiers in Endocrinology

doi 10.3389/fendo.2022.928284

5,101 views
8 citations

Case Report

Accepted on 27 Apr 2026

Case Report: Palopegteriparatide as a Novel Therapeutic Option in Pediatric Autosomal Dominant Hypocalcemia Type 1

in Pediatric Endocrinology

Arkadiusz Zygmunt
Anna Fedorczak
Lukasz Krotowski
Anna Lupinska
Kinga Salacinska
Agnieszka Gach
Michael Mannstadt
Renata Stawerska

Frontiers in Endocrinology

Original Research

Published on 06 Jul 2022

Bone Specific Alkaline Phosphatase and Serum Calcification Propensity Are Not Influenced by Etelcalcetide vs. Alfacalcidol Treatment, and Only Bone Specific Alkaline Phosphatase Is Correlated With Fibroblast Growth Factor 23: Sub-Analysis Results of the ETACAR-HD Study

in Nephrology

Katharina Dörr
Sebastian Hödlmoser
Michael Kammer
Roman Reindl-Schwaighofer
Matthias Lorenz
Bianca Reiskopf
Rahel Jagoditsch
Rodrig Marculescu
Rainer Oberbauer

Frontiers in Medicine

doi 10.3389/fmed.2022.948177

3,686 views
5 citations

Articles

Effects of active vitamin D analogues on muscle strength and falls in elderly people: an updated meta-analysis

Cholecalciferol vs. Small Doses of Alfacalcidol vs. Placebo in Chronic Kidney Disease Patients on Hemodialysis: A Randomized Parallel Group Study

Association Between Secondary Hyperparathyroidism and Body Composition in Pediatric Patients With Moderate and Advanced Chronic Kidney Disease

Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis

Efficacy and Safety of Eldecalcitol for Osteoporosis: A Meta-Analysis of Randomized Controlled Trials

Case Report: Inactivating PTH/PTHrP Signaling Disorder Type 1 Presenting With PTH Resistance

Case Report: Palopegteriparatide as a Novel Therapeutic Option in Pediatric Autosomal Dominant Hypocalcemia Type 1

Bone Specific Alkaline Phosphatase and Serum Calcification Propensity Are Not Influenced by Etelcalcetide vs. Alfacalcidol Treatment, and Only Bone Specific Alkaline Phosphatase Is Correlated With Fibroblast Growth Factor 23: Sub-Analysis Results of the ETACAR-HD Study